MSA
IBB icon

Marino Stram & Associates’s iShares Biotechnology ETF IBB Stock Holding History

Marino Stram & Associates’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-86
Closed -$9K – 502
2018
Q1 		$9K Buy
+86
New +$9.53K 0.01% 319

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Marino Stram & Associates's IBB Position: Q2 2018 in Review

Marino Stram & Associates sold out of iShares Biotechnology ETF (IBB) in Q2 2018, closing a stake of 86 shares — an estimated $9K sold.

Marino Stram & Associates first reported a position in IBB in Q1 2018 and held it in 1 quarter. The position peaked at $9K in Q1 2018. 609 funds tracked by Wall St. Rank hold IBB as of Q2 2018.

  • Marino Stram & Associates reported no remaining iShares Biotechnology ETF position as of Q2 2018 after selling out during the quarter.
  • Marino Stram & Associates sold 86 iShares Biotechnology ETF shares in Q2 2018, an estimated $9K.
  • Marino Stram & Associates first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 1 quarter.
  • Marino Stram & Associates's iShares Biotechnology ETF position peaked at $9K in Q1 2018.
  • 609 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2018.

Based on Marino Stram & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.